

# Axinn Defeats TRO, Enabling Immediate Launch of Generic Versions of AstraZeneca's Blockbuster Crestor

NEWS | 1 MIN READ

July 20, 2016

A team of attorneys from Axinn intervened on behalf of Par Pharmaceutical, Inc. and Apotex Corp. in the U.S. District Court for the District of Columbia to oppose AstraZeneca's motion for a temporary restraining order. Attorneys from several firms intervened on behalf of five other generic pharmaceutical companies as well. AstraZeneca sought the order to block the FDA from approving generic versions of its top-selling cholesterol drug, Crestor (the fifth largest blockbuster drug on the market). AstraZeneca argued that the FDA cannot approve any generic versions of Crestor because it has so-called orphan drug exclusivity for a rare pediatric use of the drug that would prevent generic competition before 2023.

On July 19, U.S. District Judge Randolph Moss held a TRO hearing at which the Axinn team argued on behalf of all of the Intervenor-Defendants. Judge Moss denied AstraZeneca's motion for a TRO, allowing generic versions of the drug to enter the market.

Last year, Axinn attorneys also [defeated a TRO](#) enabling the immediate launch of generic versions of Otsuka's blockbuster Abilify.

## Related People

---



Aziz Burgy

## Related Services

---

Intellectual Property

To subscribe to our publications, [click here](#).

## Featured Insights

- GCR Live: Law Leaders Europe 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- AHLA Annual Meeting 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- SABA North America Annual Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses  
**WEBINAR    ANTITRUST**
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025  
**SPONSORSHIP    ANTITRUST**
- NJSBA Annual Meeting and Convention 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You  
**WEBINAR    INTELLECTUAL PROPERTY**

- Hartford HealthCare Black and Red Gala 2025  
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025  
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits  
AXINN VIEWPOINTS LITIGATION & TRIALS